You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 3.239.0.0/16 has been blocked (disabled) by ‪Blablubbs‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 07:38, 2 November 2024.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪Elton‬. The reason given is Open proxy/Webhost: See the help page if you are affected: .
- Start of block: 18:08, 17 February 2024
- Expiry of block: 18:08, 17 February 2029
Your current IP address is 3.239.231.185. The blocked range is 3.239.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((Short description|Japanese pharmaceuticals company))
((More citations needed|date=June 2019))[[File:Mitsubishi Tanabe Pharma logo.jpg|right|thumb|Logo]]
[[File:Mitsubishi Tanabe Pharma.JPG|right|thumb|Mitsubishi Tanabe Pharma headquarters building]]((Infobox company
| name                = Mitsubishi Tanabe Pharma Corporation
| type                = Pharmaceutical company
| fate                = Tanabe Seiyaku Co., Ltd. merged with Mitsubishi Pharma to form Mitsubishi Tanabe Pharma
| predecessor         = Neuroderm
| founded             = 1678<ref name="EXSERVAN">((cite news|title=Mitsubishi Tanabe Pharma America Announces EXSERVAN (riluzole) is Now Available in the U.S. for the Treatment of ALS|url=https://www.biospace.com/article/releases/mitsubishi-tanabe-pharma-america-announces-exservan-riluzole-is-now-available-in-the-u-s-for-the-treatment-of-als/|date=30 June 2021|accessdate=10 May 2022|publisher=Genetic Engineering News))</ref>
| parent              = [[Mitsubishi Chemical Holdings Corporation]]
| location            = Doshomachi, [[Osaka]]<ref name="EXSERVAN"/>
| hq_location_country = [[Japan]]
))
'''Mitsubishi Tanabe Pharma Corporation''' is a Japanese [[pharmaceuticals]] company from Osaka,<ref name="EXSERVAN"/> a subsidiary of [[Mitsubishi Chemical Holdings Corporation]]. ((nihongo|'''Mitsubishi Pharma Corporation'''|三菱ウェルファーマ株式会社|Mitsubishi Werufāma Kabushiki-gaisha)) was formed in 2001 from the merger of Mitsubishi-Tokyo Pharmaceuticals and Welfide Corporation.  On October 1, 2007 Tanabe Seiyaku Co., Ltd. merged with Mitsubishi Pharma to form Mitsubishi Tanabe Pharma.<ref>[http://www.mt-pharma.co.jp/shared/show.php?url=../e/company/history.html Mitsubishi Tanabe Pharma Corporate History]</ref>

Originally founded in 1678, Mitsubishi Tanabe considers itself as one of the oldest pharmaceutical companies in the world.<ref name="EXSERVAN"/> Mitsubishi Tanabe Pharma is a member of the [[Mitsubishi UFJ Financial Group]] (MUFJ) [[keiretsu]].

==Products==
Mitsubishi-Tanabe Pharmaceuticals developed the first [[BET inhibitor]] molecules.<ref>((cite patent |country=JP |number=2008156311))</ref><ref>((cite patent |country=JP |number=H0228181))</ref>

In August 2014, the company announced three-year research collaboration agreement with [[AstraZeneca]] on [[diabetic nephropathy]], to replace dialysis or kidney transplantation.<ref name="AstraZenecaMTPC">((cite news|title=AstraZeneca and MTPC come together for research on diabetic nephropathy drugs|url=http://www.genengnews.com/gen-news-highlights/astrazeneca-mtpc-partner-to-validate-diabetic-nephropathy-targets/81250258/?kwrd=Medicines%20Company|date=20 August 2014|accessdate=21 August 2014|publisher=Genetic Engineering News))</ref>

An [[intravenous therapy|intravenous]] treatment of Mitsubishi Tanabe is Radicava (edaravone) which has the goal to slow the decline of physical function in patients with [[amyotrophic lateral sclerosis]] (ALS) and was approved by the U.S. [[Food and Drug Administration]] in 2017. The U.S. American branch of Mitsubishi Tanabe created a locator for healthcare and infusion centers.<ref name="ALS Care Centers">((cite news|title=Mitsubishi Tanabe's revamped tool finds ALS care centers for patients|url=https://www.fiercepharma.com/marketing/mitsubishi-tanabe-opens-up-als-care-locator-platform-to-patients-and-caregivers|date=22 May 2019|accessdate=10 May 2022|publisher=Fierce Pharma|last=Snyder Bulik|first=Beth))</ref>

Mitsubishe Tanabe has also an [[orally disintegrating tablet]] for ALS with Exservan ([[riluzole]]).<ref name="EXSERVAN"/> 

==Ownership history==
In 1604, Tanabeya Matazaemon is granted a license by [[Tokugawa Ieyasu]] for trade in herbal medicines with [[Luzon]] and [[Ayutthaya Kingdom|Siam]].<ref>((cite web |title=History of Mitsubishi Tanabe Pharma |url=https://www.mtpc-shiryokan.jp/en/history/ |website=Mitsubishi Tanabe Pharma Historical Museum |access-date=26 February 2022))</ref>

In 1901, ''Motosaburo Tanabe, the Twelfth'' established a [[pharmacy]] in [[Tokyo]], which incorporated in 1921 as Motosaburo Tanabe Shoten.

In 1921, Nippon Tar Industries was established.

In 1940, Takeda Kasei Co., Ltd. was established by Chobei Takeda & Co., Ltd. (present-day [[Takeda Pharmaceutical Company]]) and Nippon Kasei Chemical Co. Ltd. (present-day [[Mitsubishi Chemical Corporation]]) and built its first plant in Higashi-Yoshitomi-mura, [[Fukuoka Prefecture]].

In 1943, Motosaburo Tanabe Shoten, changed its name to Tokyo Tanabe Pharmaceuticals Co., Ltd.

In 1946, Takeda Kasei Co., Ltd. changed its name to Yoshitomi Pharmaceutical Co., Ltd.

In 1949, Yoshitomi Pharmaceutical Co., Ltd. listed on Tokyo and Osaka stock exchanges.

In 1950, The Blood Plasma Corporation of Japan was established with head office and plant in [[Osaka]]. The founders included war criminals such as [[Masaji Kitano|Kitano Masaji]] who performed torture and experimentations on humans in the Japanese military's notorious [[Unit 731]] during World War II. These crimes were recognized by the UN as extreme "crimes against humanity".

In 1952, Nippon Tar Industries became Mitsubishi Chemical Industries, Ltd.

In 1964, Blood Plasma Corporation changed its name to [[Green Cross (Japan)|Green Cross Corporation]].

In 1998, Green Cross Corporation was acquired by Yoshitomi Pharmaceutical.

In 2000, Green Cross Corporation changing its name to Welfide Corporation.

In 1981, Mitsubishi Chemical Industries, Ltd. established a business alliance with Tokyo Tanabe Pharmaceuticals Co.

In 1984, Mitsubishi Chemical Industries, Ltd. changed its name to [[Mitsubishi Chemical Corporation]] following the  merger with Mitsubishi Petrochemical Co., Ltd.

In 1999, Mitsubishi Chemical Corporation and Tokyo Tanabe Pharmaceuticals Co. merged formally and formed Mitsubishi-Tokyo Pharmaceuticals, Inc., to take over the combined pharmaceutical operations of the two companies.

In 2001, Mitsubishi-Tokyo Pharmaceuticals and Welfide Corporation merged to establish Mitsubishi Pharma Corporation, and Mitsubishi Tanabe Pharma.<ref>((cite web |title=Family Tree of Mergers at Mitsubishi Tanabe Pharma |url=https://www.mtpc-shiryokan.jp/en/history/pdf/genealogy.pdf |website=Mitsubishi Tanabe Pharma Historical Museum |access-date=26 February 2022))</ref>

In October 2005, Mitsubishi Pharma Corporation  joined again with Mitsubishi Chemical Corporation to create [[Mitsubishi Chemical Holdings Corporation]].

In July, 2017, Mitsubishi Tanabe Pharma acquired Neuroderm for $1.1 billion.<ref>((Cite news|url=http://uk.reuters.com/article/us-neuroderm-m-a-mitsub-tanabe-idUKKBN1A90IA|title = Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 billion|newspaper = Reuters|date = 24 July 2017|last1 = Cohen|first1 = Sam Nussey))</ref>

On 27 February 2020, Mitsubishi Tanabe Pharma was delisted from the Tokyo Stock Exchange, and is now described as a member of the Mitsubishi Chemical Holdings Group <ref>https://www.mt-pharma.co.jp/e/release/nr/2020/pdf/e_MTPC200226.pdf ((Bare URL PDF|date=March 2022))</ref>

==References==
((Reflist))

==External links==
* [http://www.mt-pharma.co.jp/e/index.php Mitsubishi Tanabe Pharma] ((in lang|en))
* ((cite web |url=https://www.mtpc-shiryokan.jp/en/ |title=Mitsubishi Tanabe Pharma Historical Museum )) ((in lang|en))

((Mitsubishi Chemical Holdings|state=autocollapse))
((Authority control))

[[Category:Pharmaceutical companies of Japan]]
[[Category:Companies based in Osaka Prefecture]]
[[Category:Japanese companies established in 2007]]
[[Category:Pharmaceutical companies established in 2007]]
[[Category:Companies formerly listed on the Tokyo Stock Exchange]]
[[Category:Life sciences industry]]
[[Category:Mitsubishi companies]]
[[Category:Midori-kai]]
[[Category:Mitsubishi Chemical Holdings]]

Pages transcluded onto the current version of this page (help):

Mitsubishi Tanabe Pharma (edit)
Template:Ambox (view source) (template editor protected)
Template:Authority control (view source) (template editor protected)
Template:Bare URL PDF (view source) (template editor protected)
Template:Category handler (view source) (protected)
Template:Citation/make link (view source) (protected)
Template:Citation/styles.css (view source) (template editor protected)
Template:Cite news (view source) (protected)
Template:Cite patent (view source) (template editor protected)
Template:Cite patent/core (view source) (template editor protected)
Template:Cite web (view source) (protected)
Template:Comma separated entries (view source) (template editor protected)
Template:Delink (view source) (protected)
Template:Find sources mainspace (view source) (template editor protected)
Template:Fix (view source) (protected)
Template:Fix/category (view source) (protected)
Template:Hlist/styles.css (view source) (protected)
Template:In lang (view source) (template editor protected)
Template:Infobox (view source) (template editor protected)
Template:Infobox company (view source) (template editor protected)
Template:Main other (view source) (protected)
Template:Mitsubishi Chemical Holdings (edit)
Template:More citations needed (view source) (template editor protected)
Template:Navbox (view source) (template editor protected)
Template:Nihongo (view source) (template editor protected)
Template:Pagetype (view source) (protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Template:SDcat (view source) (protected)
Template:Short description (view source) (protected)
Template:Short description/lowercasecheck (view source) (protected)
Template:Template other (view source) (protected)
Template:Wikidata (view source) (template editor protected)
Module:Arguments (view source) (protected)
Module:Authority control (view source) (template editor protected)
Module:Authority control/config (view source) (template editor protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for clobbered parameters (view source) (template editor protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Delink (view source) (protected)
Module:Disambiguation/templates (view source) (protected)
Module:EditAtWikidata (view source) (protected)
Module:Exponential search (view source) (template editor protected)
Module:Find sources (view source) (template editor protected)
Module:Find sources/config (view source) (template editor protected)
Module:Find sources/links (view source) (template editor protected)
Module:Find sources/templates/Find sources mainspace (view source) (template editor protected)
Module:In lang (view source) (template editor protected)
Module:Infobox (view source) (template editor protected)
Module:Infobox/styles.css (view source) (template editor protected)
Module:InfoboxImage (view source) (template editor protected)
Module:Lang (view source) (template editor protected)
Module:Lang/ISO 639 synonyms (view source) (template editor protected)
Module:Lang/data (view source) (template editor protected)
Module:Language/data/iana languages (view source) (template editor protected)
Module:Language/data/iana regions (view source) (template editor protected)
Module:Language/data/iana scripts (view source) (template editor protected)
Module:Language/data/iana suppressed scripts (view source) (template editor protected)
Module:Language/data/iana variants (view source) (template editor protected)
Module:Message box (view source) (protected)
Module:Message box/ambox.css (view source) (protected)
Module:Message box/configuration (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Navbox (view source) (template editor protected)
Module:Navbox/configuration (view source) (template editor protected)
Module:Navbox/styles.css (view source) (template editor protected)
Module:Nihongo (view source) (template editor protected)
Module:Pagetype (view source) (protected)
Module:Pagetype/config (view source) (protected)
Module:Pagetype/disambiguation (view source) (protected)
Module:Pagetype/setindex (view source) (protected)
Module:Pagetype/softredirect (view source) (protected)
Module:SDcat (view source) (protected)
Module:Separated entries (view source) (protected)
Module:String (view source) (protected)
Module:TableTools (view source) (protected)
Module:Unicode data (view source) (template editor protected)
Module:Unicode data/scripts (view source) (template editor protected)
Module:Unsubst (view source) (protected)
Module:Wd (view source) (template editor protected)
Module:Wd/i18n (view source) (template editor protected)
Module:WikidataIB (view source) (template editor protected)
Module:WikidataIB/nolinks (view source) (template editor protected)
Module:WikidataIB/titleformats (view source) (template editor protected)
Module:Wikitext Parsing (view source) (protected)
Module:Yesno (view source) (protected)

Return to Mitsubishi Tanabe Pharma.

Retrieved from "https://en.wikipedia.org/wiki/Mitsubishi_Tanabe_Pharma"